Structural topology defines protective CD8
AIDS Vaccines
/ genetics
Acquired Immunodeficiency Syndrome
/ prevention & control
Alleles
CD8-Positive T-Lymphocytes
/ immunology
Conserved Sequence
Epitopes, T-Lymphocyte
/ genetics
HIV-1
/ immunology
HLA-B Antigens
/ genetics
Histocompatibility Antigens Class I
/ genetics
Humans
Mutation
Proteome
/ genetics
Virus Replication
gag Gene Products, Human Immunodeficiency Virus
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
03 05 2019
03 05 2019
Historique:
received:
23
09
2018
accepted:
25
03
2019
entrez:
4
5
2019
pubmed:
3
5
2019
medline:
2
11
2019
Statut:
ppublish
Résumé
Mutationally constrained epitopes of variable pathogens represent promising targets for vaccine design but are not reliably identified by sequence conservation. In this study, we employed structure-based network analysis, which applies network theory to HIV protein structure data to quantitate the topological importance of individual amino acid residues. Mutation of residues at important network positions disproportionately impaired viral replication and occurred with high frequency in epitopes presented by protective human leukocyte antigen (
Identifiants
pubmed: 31048489
pii: 364/6439/480
doi: 10.1126/science.aav5095
pmc: PMC6855781
mid: NIHMS1055203
doi:
Substances chimiques
AIDS Vaccines
0
Epitopes, T-Lymphocyte
0
HLA-B Antigens
0
HLA-B57 antigen
0
Histocompatibility Antigens Class I
0
Proteome
0
gag Gene Products, Human Immunodeficiency Virus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
480-484Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI100663
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI067854
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI104715
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11530-5
pubmed: 21690407
Immunity. 2008 Dec 19;29(6):1009-21
pubmed: 19062316
J Exp Med. 2004 Apr 5;199(7):905-15
pubmed: 15067030
PLoS Pathog. 2017 Aug 7;13(8):e1006541
pubmed: 28787455
Nature. 2011 Jan 20;469(7330):424-7
pubmed: 21248851
Nature. 2004 Dec 9;432(7018):769-75
pubmed: 15592417
Blood. 2013 Jan 31;121(5):801-11
pubmed: 23233659
Trends Biochem Sci. 2015 Feb;40(2):101-7
pubmed: 25600289
AIDS. 2013 Mar 27;27(6):899-905
pubmed: 23276808
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7151-E7158
pubmed: 27799557
Immunogenetics. 1999 Nov;50(3-4):201-12
pubmed: 10602880
Immunity. 2007 Sep;27(3):406-16
pubmed: 17892849
Nat Med. 2007 Jan;13(1):46-53
pubmed: 17173051
Immunity. 2013 Mar 21;38(3):606-17
pubmed: 23521886
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
PLoS One. 2007 Oct 03;2(10):e984
pubmed: 17912361
J Virol. 2013 May;87(10):5461-7
pubmed: 23468488
Science. 2007 Aug 17;317(5840):944-7
pubmed: 17641165
EBioMedicine. 2014 Dec 22;2(1):46-58
pubmed: 26137533
Expert Rev Vaccines. 2014 Dec;13(12):1489-500
pubmed: 25163695
J Exp Med. 2003 May 19;197(10):1365-75
pubmed: 12743169
PLoS Pathog. 2007 Nov;3(11):e157
pubmed: 18052528
J Virol. 2009 Aug;83(15):7641-8
pubmed: 19458000
PLoS Pathog. 2013;9(6):e1003461
pubmed: 23818857
N Engl J Med. 2001 May 31;344(22):1668-75
pubmed: 11386265
Nat Commun. 2016 May 23;7:11660
pubmed: 27212475
PLoS One. 2013 Jun 13;8(6):e66065
pubmed: 23785468